Liver Disease Treatment Market Expected to Reach $36,455.70 Million by 2030 | CAGR of 5.7%

According to a new report published by Allied Market Research, titled, " Liver Disease Treatment Market by Treatment Type, Disease Type and Region: Global Opportunity Analysis and Industry Forecast, 2021–2030," the global liver disease treatment market size was valued at $20,673.70 million in 2020, and is estimated to reach $36,455.70 million by 2030, growing at a CAGR of 5.7% from 2021 to 2030.

Liver is one of the most important organs in the human body, since it eliminates unwanted substances from the blood, regulates chemical levels in the body, and stores nutrients for all cellular and biological activity. The phrase "liver disease" refers to a wide range of issues that cause the liver to fail to perform its primary function. Hepatitis, cirrhosis, liver cancer, and liver abscess are examples of liver diseases.

Liver problems can be caused by a variety of factors that damage the liver, such as viruses, alcohol use, and obesity. Viruses, alcohol consumption, and obesity are all examples of conditions that can harm the liver. Damage to the liver over time can cause scarring (cirrhosis), which can lead to liver failure, which is a life-threatening condition. However, early treatment may enable the liver to recover.

Increase in alcohol consumption leads to death of healthy liver cells and reduces the ability to generate new ones as well as leads to buildup of fats leading to liver diseases. For instance, according to the National Center for Drug Abuse Statistics 2021, about 34.1% reported binge drinking at least once and 7.0% reported extreme binge drinking. Furthermore, a survey conducted by Johns Hopkins University of Maryland Baltimore, about 60.1% of participants report drinking more alcohol after March 1, 2020. Thus, such high alcohol consumption is expected to lead to liver disorders and further drive the growth of the liver disease treatment market.

In addition, in March 2021, Gilead Sciences, Inc. and Novo Nordisk A/S announced that the companies have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH). It will conduct a Phase 2b double-blind, placebo-controlled research to investigate the safety and efficacy of Novo Nordisk’s semaglutide and Gilead’s investigational FXR agonist cilofexor and investigational ACC inhibitor firsocostat to determine the treatments impact on liver fibrosis improvement in individuals with compensated cirrhosis (F4) due to NASH. Thus, such collaborations by key players for liver disease treatment significantly boosts the market growth.

Hepatitis is a liver inflammation caused by a variety of infectious and non-infectious viruses, which can cause a variety of health problems, some of which are fatal. Hepatitis types A, B, C, D, and E refer to the five primary strains of the hepatitis virus and they all cause liver diseases. According to the World Health Organization, an estimated 4.5 million premature deaths could be prevented in low and middle income countries by 2030 through vaccination, diagnostic tests, medicines, and education campaigns. Hepatitis B or C affects an estimated 354 million people globally, and testing and treatment are out of reach for the vast majority. Thus, rise in hepatitis cases and unmet medical demand in developing countries are anticipated to offer remunerative opportunity for key players to invest in upcoming years.

The growth of the liver disease treatment market is majorly driven by technological developments in molecular imaging, increase in geriatric population, adoption of unhealthy lifestyle, surge in overweight & obese patients, and increase in public–private efforts for liver disease awareness, and financing for advanced research.

However, stringent government regulations (FDA, MHRA), high and cost of R&D for new drugs research & development, and side effects associated with certain drugs are expected to impede the market growth.

The global liver disease treatment market is segmented into treatment type, disease type, and region. On the basis of treatment type, the market is segregated into antiviral drugs, immunosuppressant’s, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy drugs. The antiviral drugs segment generated maximum revenue in 2020, accounting $8,801.50 million. The immunosuppressant segment is expected to witness highest CAGR of 7.50% during the forecast period.

By disease type, the market is fragmented into hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and others (congenital hepatic fibrosis and biliary atresia). The hepatitis segment generated maximum revenue in 2020, accounting $17,337.70 million. The cancer segment is expected to witness highest CAGR of 7.80% during the forecast period.

North America accounted for a majority of the global liver disease treatment market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to increase in consumption of alcohol, unhealthy lifestyle leading to obesity & weight gain, presence of key players, and rise healthcare expenditure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in R&D activities, surge in liver diseases, unmet medical demands, and increase in investments in the healthcare sector in the region.

Key Findings Of The Study

• By treatment type, antiviral drugs were the highest contributor to the liver disease treatment market in 2020.
• By disease type, hepatitis segment exhibited the highest growth in 2020, and is expected to continue this trend during the forecast period.
• By region, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.